Celgene's (CELG +0.8%) pomalidomide, in combination with a low dose of the steroid...
Tuesday, December 11, 2012, 9:33 AM ETCelgene's (CELG +0.8%) pomalidomide, in combination with a low dose of the steroid dexamethasone, helped patients with multiple myeloma live a median 3.6 months without their disease worsening in a Phase III study. That's above the 1.8 months for the blood cancer patients taking just a high dose of the steroid. The FDA is due to decide whether to approve pomalidomide by Feb 10. Analysts reckon pomalidomide could generate sales of over $1B/year by 2017. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles